The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 13, 2020

Filed:

May. 09, 2016
Applicants:

Biontech Cell & Gene Therapies Gmbh, Mainz, DE;

03;tron—translationale Onkologie an Der Universitátsmedizin Der Johannes Gutenberg—universität Mainz Gemeinnützige Gmbh, Mainz, DE;

Inventors:

Ugur Sahin, Mainz, DE;

Katharina Reinhard, Mainz-Kostheim, DE;

Petra Simon, Mainz, DE;

Karolina Anna Mroz, Wiesbaden, DE;

Kathleen Hobohm, Kelkheim i. Ts., DE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); A61K 39/00 (2006.01); A61K 9/127 (2006.01); A61K 39/395 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61K 9/127 (2013.01); A61K 39/0011 (2013.01); A61K 39/00111 (2018.08); A61K 39/001112 (2018.08); A61K 39/001113 (2018.08); A61K 39/001124 (2018.08); A61K 39/001168 (2018.08); A61K 39/001182 (2018.08); A61K 39/001188 (2018.08); A61K 39/001195 (2018.08); A61K 39/39558 (2013.01); C07K 14/7051 (2013.01); C07K 16/28 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/53 (2013.01); A61K 2300/00 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01);
Abstract

The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to a method for stimulating, priming and/or expanding in vivo T cells genetically modified to express a chimeric antigen receptor (CAR) targeted to an antigen, comprising contacting the T cells with the antigen or a variant thereof in vivo. In one embodiment, the antigen or variant thereof is provided by administering a nucleic acid encoding the antigen or variant thereof.


Find Patent Forward Citations

Loading…